- Report
- February 2026
- 250 Pages
Global
From €4067EUR$4,490USD£3,509GBP
- Report
- June 2026
- 159 Pages
Global
From €5299EUR$5,850USD£4,572GBP
- Report
- June 2026
- 568 Pages
Global
From €6336EUR$6,995USD£5,466GBP
- Report
- March 2026
- 136 Pages
Global
From €3622EUR$3,999USD£3,125GBP
- Report
- April 2026
- 120 Pages
Global
From €5389EUR$5,950USD£4,650GBP
- Report
- January 2026
- 180 Pages
Global
From €3211EUR$3,545USD£2,770GBP
€3568EUR$3,939USD£3,078GBP
- Report
- February 2026
- 250 Pages
Global
From €4067EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4067EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4067EUR$4,490USD£3,509GBP
- Report
- June 2026
- 573 Pages
Global
From €5299EUR$5,850USD£4,572GBP
- Report
- October 2025
- 94 Pages
Asia Pacific
From €4393EUR$4,850USD£3,790GBP
- Report
- January 2025
- 240 Pages
Global
From €2581EUR$2,850USD£2,227GBP
- Report
- April 2023
- 177 Pages
Global
From €3782EUR$4,175USD£3,263GBP
- Report
- December 2022
- 280 Pages
Global
From €2174EUR$2,400USD£1,876GBP
- Report
- April 2026
- 141 Pages
China
From €3622EUR$3,999USD£3,125GBP
- Report
- July 2024
- 136 Pages
Global
From €2264EUR$2,500USD£1,954GBP
From €3170EUR$3,500USD£2,735GBP
- Report
- August 2023
- 145 Pages
Global
From €2853EUR$3,150USD£2,462GBP
- Report
- February 2024
- 95 Pages
Europe
From €4302EUR$4,750USD£3,712GBP
- Report
- February 2024
- 135 Pages
Global
From €4302EUR$4,750USD£3,712GBP

The Presymptomatic Testing market within the context of Genomics is a rapidly growing sector of the healthcare industry. It involves the use of genetic testing to identify individuals who are at risk of developing a particular disease before any symptoms appear. This type of testing can be used to identify genetic mutations that may lead to the development of a disease, allowing for early intervention and prevention. It can also be used to identify individuals who are at risk of passing on a genetic disorder to their children.
Presymptomatic testing is becoming increasingly popular as it allows for early detection and treatment of diseases, which can improve patient outcomes and reduce healthcare costs. It is also being used to identify individuals who may be at risk of developing certain types of cancer.
Companies in the Presymptomatic Testing market include 23andMe, Color Genomics, Invitae, Counsyl, and Myriad Genetics. Show Less Read more